[A trial of the intranasal vaccination of adults against measles: the approaches to an alternative revaccination method].
The safety and efficacy of a measles vaccine from the L-16 strain was studied after its intranasal administration to adult volunteers using an atomizer. The controls were adult volunteers given one dose of the vaccine subcutaneously. The measles vaccine given intranasally was used in the same or double dose. The intranasal administration of the vaccine caused practically no side effects. Within 14-60 days postvaccination, the volunteers in all the groups showed a significant rise in titres of antibodies to measles virus determined by hemagglutination inhibition test. The double dose of intranasally administered vaccine was approximately as effective as a single dose given subcutaneously.